PlainPharmaWatch

CMS Open Payments · Program Year 2024

Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. reported $1,669,960.78 in payments to 28,289 physicians and teaching hospitals across 28,319 transactions.

See the rankings → How this is sourced
$1.7M
Total payments
28,319
Transactions
28,289
Recipients
+$36.8K
General Payments vs PY2023

Xeris Pharmaceuticals, Inc. reported $1,669,960.78 in payments to 28,289 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #493 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $59.03 per recipient across 5 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Xeris Pharmaceuticals, Inc. pairs above-median payment volume with an unusually diversified payment pattern across a wide recipient base.

#493
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
5
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Xeris Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $36.8K (+3.2%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: XERIS PHARMACEUTICALS, INC.PY2023: XERIS PHARMACEUTICALS, INC.PY2024: Xeris Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.1MPY2024$1.2M
PY2023
$1,138,033.80
PY2024
$1,174,861.27

How Xeris Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Xeris Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,669,961 Top 26% higher than 74% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Xeris Pharmaceuticals, Inc.

Rank #493 of 1,925 companies in CMS Open Payments for 2024 belongs to Xeris Pharmaceuticals, Inc., which reported $1,669,960.78 across 28,319 transactions to 28,289 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $58.97 per transaction and $59.03 per recipient.

The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $598.1K, accounting for 35.8% of the company's reported total and 27,679 transactions.

General Payment Breakdown by Type

Xeris Pharmaceuticals, Inc. made 5 types of general payments. "Food and Beverage" is the largest category at $598.1K, 35.8% of the company's reported total.

How Xeris Pharmaceuticals, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Food and Beverage$598.1K2. Honoraria$416.6K3. Travel and Lodging$65.0K4. Consulting Fee$60.9K5. Education$34.2K
Payment Type Amount Transactions
Food and Beverage $598.1K 27,679
Honoraria $416.6K 241
Travel and Lodging $65.0K 253
Consulting Fee $60.9K 14
Education $34.2K 102

Recipient Concentration in General Payments

The five largest recipient relationships account for $230,762.90 (19.6%) of $1,174,861.27 in this company's General Payments records across 12,975 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Xeris Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Jeffrey Sherman$62.8KPhilip Rabito$60.7KJohn Paes$38.4KElena Christofides$37.4KJessica R Adkins$31.5K
  1. 1

    Jeffrey Sherman

    $62,772.50 across 25 reported transactions

  2. 2

    Philip Rabito

    $60,674.92 across 77 reported transactions

  3. 3

    John Paes

    $38,402.04 across 52 reported transactions

  4. 4

    Elena Christofides

    $37,389.19 across 57 reported transactions

  5. 5

    Jessica R Adkins

    $31,524.25 across 63 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $58.97. Average per recipient: $59.03.

Total Amount

$1,669,960.78

Avg per Transaction

$58.97

Avg per Recipient

$59.03

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Xeris Pharmaceuticals, Inc. Share

0.0%

#493 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Xeris Pharmaceuticals, Inc.

EMD Serono Research & Development Institute, Inc.

$1.7M 80 recipients

Sebela Women's Health Inc.

$1.7M 19 recipients

KARL STORZ Endoscopy-America

$1.7M 1,585 recipients

Gen-Probe, Inc.

$1.6M 250 recipients

ABK Biomedical USA, Inc.

$1.6M 49 recipients

Patterson Companies, Inc.

$1.7M 7,273 recipients

Frequently Asked Questions

How much did Xeris Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $1,669,960.78 from Xeris Pharmaceuticals, Inc. to physicians and hospitals across 28,319 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Xeris Pharmaceuticals, Inc.? ▾
28,289 physicians and teaching hospitals received payments from Xeris Pharmaceuticals, Inc. in 2024, averaging $59.03 per recipient.
What types of payments did Xeris Pharmaceuticals, Inc. make? ▾
General payments from Xeris Pharmaceuticals, Inc. span 5 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Food and Beverage" at $598.1K, representing 35.8% of the company's reported total.
How does Xeris Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
Xeris Pharmaceuticals, Inc. ranks #493 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Xeris Pharmaceuticals, Inc.? ▾
In 2024, Xeris Pharmaceuticals, Inc. averaged $58.97 per transaction across 28,319 transactions to 28,289 recipients.
Where does the payment data for Xeris Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Xeris Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.